文档介绍：低分子肝素联合瑞舒伐他汀与醋酸泼尼松治疗肾病综合征患者的临床效果
 
   
 
 
 
 
 
 
 
     
 
 
 
 
 
　　摘要：目的  探討低分子肝素结合瑞舒伐他汀与醋酸泼尼松治疗肾病综合征患者的效果。方法  选择2018年1月～2019年1月我院收治的肾病综合征患者80例作为研究对象，根据随机数字表法分为对照组和观察组，每组40例。对照组口服瑞舒伐他汀钙片+醋酸泼尼松片治疗，观察组在对照组基础上联合低分子肝素注射液治疗，比较两组治疗前后肾功能[血浆白蛋白（ALB）、血肌酐（Scr）、尿素氮（BUN）、24 h尿蛋白定量]、炎症因子[肿瘤坏死因子-α（TNF-α）、白细胞介素-1（IL-1）、白细胞介素-6（IL-6）]及血脂水平[总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）]。结果  治疗后，观察组Scr、BUN、ALB及24 h尿蛋白定量低于对照组，差异有统计学意义（P<）;观察组IL-6、TNF-α、IL-1、TC、TG、LDL-C水平均低于对照组，HDL-C水平高于对照组，差异有统计学意义（P<）。结论  低分子肝素联合瑞舒伐他汀与醋酸泼尼松治疗肾病综合征患者效果确切，有助于改善肾功能，降低炎性因子水平及血脂水平。
　　关键词：肾病综合征;低分子肝素;瑞舒伐他汀;肾功能炎症因子
窗体底端
窗体顶端
Abstract: Objective To investigate the effect of low molecular weight heparin combined with rosuvastatin and prednisone acetate in the treatment of nephrotic syndrome. Methods: 80 patients with nephrotic syndrome admitted to our hospital from January 2018 to January 2019 were selected as the study objects. According to the random number table method, they were pided into control group and observation group, 40 cases in each group. The control group was treated with rosuvastatin calcium tablets plus prednisone acetate tablets, and the observation group was treated with low molecular weight heparin injection on the basis of the control group. Renal function (ALB, SCR, bun, 24) before and after treatment were compared between the two groups H urine protein q